Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...
The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...
A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...
Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback